Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis

Chee Kian Chew, Bart L. Clarke

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1–34 [rhPTH (1–34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1–34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
StatePublished - Mar 1 2017


  • Abaloparatide
  • Anabolic agents
  • Fractures
  • Osteoporosis
  • PTHrP 1–34

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • Obstetrics and Gynecology


Dive into the research topics of 'Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis'. Together they form a unique fingerprint.

Cite this